Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas

NCT01263418 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No patients enrolled and funding has been withdrawn.

Conditions

Lymphoma, Non-Hodgkin
Lymphoma, Follicular
Lymphoma, B-Cell, Marginal Zone
Lymphoma, Low-Grade
Lymphoma, Intermediate-Grade

Interventions

DRUG: Ofatumumab

Sponsor

UNC Lineberger Comprehensive Cancer Center

Collaborators

[object Object]